Spontaneous rectus sheath hematoma: an analysis of 15 cases
|
|
|
- Shon Hampton
- 10 years ago
- Views:
Transcription
1 Turkish Journal of Trauma & Emergency Surgery Original Article Ulus Travma Acil Cerrahi Derg 2010;16 (6): Klinik Çalışma Spontaneous rectus sheath hematoma: an analysis of 15 cases Spontan rektus kılıf hematomu: 15 olgunun analizi Sinan ÇARKMAN, Volkan ÖZBEN, Kağan ZENGİN, Erkan SOMUNCU, Adem KARATAŞ BACKGROUND Spontaneous rectus sheath hematoma (RSH) is an uncommon and frequently misdiagnosed cause of acute abdominal pain. The purpose of this study is to present our experiences in the diagnosis and treatment of spontaneous RSH. METHODS This is a retrospective study of the medical histories of 15 patients admitted to our emergency surgery unit between January 2000 and July 2009 and diagnosed with spontaneous RSH (12 females, 3 males; mean age, 64.5 years; range, years). RESULTS All cases presented with acute abdominal pain or abdominal wall mass, or both. Eleven of the cases (73%) had been receiving some form of anticoagulation therapy. The leading indications for anticoagulation and/or anti-platelet therapy were atrial fibrillation in 5 patients (33%) and mitral valve replacement in 3 patients (20%). Diagnosis was made by abdominal ultrasonography and/or computerized tomography in 14 patients (93%). Twelve (80%) of the 15 patients were discharged uneventfully after conservative management following a mean hospital stay of 8.8 days (range, 3-24 days). The mortality rate was 20%. CONCLUSION Spontaneous RSH must be suspected in patients with advanced age who are using anticoagulation medications and present with acute abdominal pain. Early diagnosis permits conservative management and avoids unnecessary surgical interventions. Key Words: Acute abdomen; anticoagulant therapy; diagnosis; rectus sheath hematoma; spontaneous; treatment. AMAÇ Spontan rektus kılıf hematomu (RKH) akut karın ağısının sıklıkla gözden kaçan nadir bir nedenidir. Bu çalışmada, spontan RKH nin tanı ve tedavisindeki tecrübelerimizi sunmayı amaçladık. GEREÇ VE YÖNTEM Bu çalışmada, Ocak 2000-Temmuz 2009 tarihleri arasında acil cerrahi polikliniğine başvuran ve spontan RKH tanısı alan 15 hastanın (12 kadın, 3 erkek; ortalama yaş 64,5 yıl; dağılım yıl) tıbbi kayıtları retrospektif olarak incelendi. BULGULAR Tüm olguların başvuru nedeni akut karın ağrısı ve/veya karında kitle idi. Toplam 11 olgu (%73) antikoagülan ve/ veya antiagregan tedavisi almaktaydı. Antikoagülan/antiagregan tedavisin endikasyonları arasında en sık olanları 5 hastada (%33) atriyel fibrilasyon ve 3 hastada (%20) mitral kapak replasmanı yer almakta idi. Tanı 14 olguda (%93) karın ultrasonografisi ve/veya bilgisayarlı tomografi ile kondu. Hastaların 12 si (%80) ortalama 8,8 gün (dağılım 3-24 gün) yatış süresi sonrası konservatif tedavi ile sorunsuz bir şekilde taburcu edildi. Mortalite oranı %20 idi. SONUÇ Akut karın ağrısı ile başvuran ve antikoagülan tedavisi almakta olan ileri yaş hastalarında spontan RKH den şüphe edilmelidir. Erken tanı konservatif tedaviye olanak sağlayarak gereksiz cerrahi girişimleri önler. Anahtar Sözcükler: Akut karın; antikoagülan tedavi; tanı; rektus kılıf hematomu; spontan; tedavi. Department of General Surgery, Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey. İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, İstanbul. Correspondence (İletişim): Volkan Özben, M.D. İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, Kürsü Sekreterliği, 6. Kat, Cerrahpaşa, Fatih İstanbul, Turkey. Tel: Fax (Faks): (e-posta): [email protected] 532
2 Spontaneous rectus sheath hematoma Rectus sheath hematoma (RSH) is a relatively uncommon condition and often a clinically misdiagnosed cause of acute abdominal pain. It is caused by hemorrhage into the rectus sheath, which is caused by damage to the superior or inferior epigastric arteries or their branches, or by direct damage to the rectus muscle. [1,2] It is usually localized in the lower abdominal wall. [3] Many causes of RSH have been described, including trauma, anticoagulation medications, medication injection, hematological and coagulation disorders, increased abdominal pressure from straining, pregnancy, and hypertension. [1,2,4,5] The most frequent predisposing factor is anticoagulation therapy. Women are more prone to RSH than men. Although most cases are self-limiting, RSH can lead to significant morbidity and its overall mortality rate is reported as 4%. [5] The most commonly presented feature is a painful lower abdominal mass that never crosses the midline. [3] If RSH is suspected, the diagnosis is made on the basis of history, physical examination, ultrasonography (US) and computerized tomography (CT) findings. With early diagnosis and conservative management, surgical intervention can be avoided even with large hematoma. Surgery would be necessary in cases in which hemodynamic stability is not achieved. Early diagnosis is mandatory in order to prevent unnecessary surgical interventions. [6] In this retrospective study, we aimed to report our experiences with 15 cases including the previously reported five cases [2] diagnosed with nontraumatic or spontaneous RSH. MATERIALS AND METHODS We retrospectively reviewed the medical records of patients who had been consecutively registered and diagnosed with RSH at our emergency surgery unit between January 2000 and July The search yielded 19 potential cases. Four cases were excluded as they had alternate diagnoses such as postsurgical RSH and fall-offs. The demographic data (sex, age at diagnosis Table 1. Clinical characteristics of patients diagnosed with spontaneous RSH No Age/ Past medical Previous Physical INR on Radiological Treatment Hospital Outcome Sex history medication signs admission study stay (d) 1 74/F AF Warfarin Tender mass 1.81 None Surgery (HI) 5 Exitus 2 53/F COPD None Tender mass 1.11 CT Conservative 7 Exitus 3 65/F AF Warfarin Tender mass 1.48 US + CT Conservative 3 Discharged 4 72/F Acute coronary Warfarin Tender mass 2.34 US + CT Conservative 21 Discharged syndrome in both lower Q + peri-umbilicus 5 73/F MVR Warfarin Tender mass 1.96 US + CT Conservative 16 Discharged 6 64/F HT Anti-platelet Tx Mass in right * US + CT Conservative 4 Discharged lower Q 7 77/F AF Anti-platelet Tx Tender mass US Conservative 6 Discharged 8 72/F MVR Warfarin Tender mass 1.80 US + CT Conservative 10 Discharged + LMWH in both lower Q 9 49/F SLE LMWH Tender mass None CT Conservative 24 Discharged 10 79/M MI Warfarin Tenderness 2.39 US + CT Conservative 3 Discharged in left upper Q 11 79/F AVR Warfarin Tender mass 5.09 US Conservative 7 Discharged 12 62/F MVR Warfarin Tenderness None US + CT Conservative 3 Discharged 13 68/M AF LMWH Tender mass None US + CT Conservative 7 Exitus in right upper Q (infected hematoma) 14 60/F AF Warfarin Tender mass 3.5 CT Surgery (HI) 13 Discharged (infected hematoma) 15 20/M Factor VIII deficiency None Mass CT Conservative 5 Discharged * Bleeding time >12 min, Bleeding time >9 min, APTT (activity partial thromboplastin time ) = 154 s (normal range, s). LMWH: Low-molecular-weight heparin; AF: Atrial fibrillation; COPD: Chronic obstructive pulmonary disease; HT: Hypertension; MVR: Mitral valve replacement; AVR: Aortic valve replacement; MI: Myocardial infarction; SLE: Systemic lupus erythematosus; HI: Hemodynamic instability; Q: Quadrant; Tx: Treatment. Cilt - Vol. 16 Sayı - No
3 Ulus Travma Acil Cerrahi Derg of RSH), clinical characteristics and comorbid conditions, predisposing medications, and presenting signs and symptoms of the patients were evaluated. International normalized ratio (INR) results, radiological (US and CT) findings, treatment approaches, length of hospital stay, and patient outcomes were also documented. RESULTS Fifteen patients were hospitalized with the diagnosis of spontaneous RSH. The clinical features of the patients are summarized in Table 1. Twelve of the 15 patients were female (80%), with a female to male ratio of 4:1. Their ages ranged from 20 to 79 years (mean age, 64.5 years). All patients presented with either abdominal pain or abdominal wall mass, or both. Hemodynamic instability was detected in 2 patients. A total of 11 patients (73%) were receiving some form of anticoagulation therapy: 8 (53%) were on warfarin alone, 2 (13%) were on low-molecular-weight heparin (LMWH) injections, and 1 was on both warfarin and LMWH. Two patients were receiving anti-platelet (aspirin) treatment. The indications for anticoagulation and/or anti-platelet therapy were atrial fibrillation in 5 (33%) and mitral valve replacement in 3 (20%), and the other indications were aortic valve replacement, myocardial infarction, acute coronary syndrome, hypertension, and systemic lupus erythematosus. Chronic obstructive pulmonary disease in 1 case and factor VIII deficiency in 1 case were also detected. The most common presenting symptom was acute abdominal pain followed by an abdominal wall mass. Physical abdominal examination revealed a tender mass or tenderness in all of the cases. INR ranged from 1.11 to The diagnosis was made by abdominal CT (Fig. 1) and/or US in 14 patients (93%), and US was utilized for the follow-up. Thirteen patients (87%) were treated nonsurgically with red blood cells (4-11 units), fresh frozen plasma infusions (4-8 units), and vitamin K as required. Surgical evacuation of large and/or infected hematoma and hemostasis were performed in 2 patients (13%). Mean length of hospital stay was 8.6 days (range, 3-24 days). There were 3 fatal cases with a mortality rate of 20%. DISCUSSION RSH is a rare but well-documented clinical entity with an elusive diagnosis. Clinical presentation, past medical history and previous medications in these patients should be carefully questioned in order to obtain valuable information for the correct diagnosis. RSH demonstrates a female to male ratio of 2-3:1, with the highest incidence in the fifth decade. It accounts for up to 2% of cases of unexplained abdominal pain and may occur more often in the right lower quadrant. [2,5,7,8] The present study includes RSH cases who presented with no apparent abdominal trauma such as surgical trauma or falls. Although we found one young patient with hemophilia A, the mean age was 64.5 years (peak age, 79 years). This may be because older patients are more likely to be receiving anticoagulation and/or anti-platelet therapy. [1] The female to male ratio was 4:1, slightly higher than in the earlier reports. [1,7] Other than blunt abdominal trauma, RSH typically occurs in patients who receive anticoagulant or fibrinolytic treatment and in severe hypocoagulability states such as hemophilia and von Willebrand disease. [9] Hemorrhage is the major complication of anticoagulation therapy. The risk of hemorrhage is correlated with the underlying patient characteristics, intensity of anticoagulation and length of the therapy. A similar risk of bleeding is associated with LMWH [10,11] and anti-platelet (acetylsalicylic acid) therapy. The concurrence of synergic side effects from different anti-thrombotics (a) Fig. 1. The abdominal CT appearance of spontaneous RSH in a female patient who had been taking warfarin prior to hospital admission (a). The hematoma arose from the left rectus muscle (arrow). The urinary bladder (UB) was shifted to the right with the expansion of the hematoma to the intraperitoneal cavity (arrowhead). Following conservative treatment, complete resolution of the hematoma was seen on follow-up CT after 12 months (b). 534 Kasım - November 2010 (b)
4 Spontaneous rectus sheath hematoma will be a growing clinical problem due to the vulnerability of the aged populations and the increasing incidence of age-related diseases such as thrombosis. [9] In our series, 13 patients (86%) were already on some form of anticoagulation and/or anti-platelet therapy on admission. Thus, we highlight the fact that the use of these drugs even in prophylactic doses requires prudent application and deliberate follow-up during their use, especially in the elderly. Both US and CT have been used as diagnostic aids to differentiate between RSH and any intra-abdominal pathology. [5] US may be useful in the diagnosis of RSH, but with a sensitivity rate ranging from only 70% to 90%. CT is useful in excluding other intraabdominal conditions, and is the gold standard, with 100% sensitivity and specificity. [4,7,12] Magnetic resonance imaging is used for long-standing hematomas whenever there is difficulty in distinguishing between a soft tissue tumor and RSH on the CT scan. [4,13] We identified that the findings on the US and CT reports were diagnostic in all of the cases except for one who needed an emergent surgical evacuation of the hematoma due to hemodynamic instability. Infraumbilical localization of the hemorrhage was detected in the majority of our patients (87%). This can be explained by the anatomy of the rectus abdominis muscle below the arcuate line where the posterior rectus sheath passes anteriorly and allows a greater movement of the lower portion of the muscle but also predisposes to vessel rupture with accumulation of large hematomas. [14] As the lesion is self-limited, most RSH can be treated conservatively with analgesia, the treatment of predisposing conditions and cessation of the anticoagulation. When necessary, the coagulation profile should be corrected with the administration of vitamin K, fresh frozen plasma and protamine sulfate in patients being treated with heparin [2,5,11] or, as in our case, factor VIII replacement in patients with hemophilia A. Recombinant VIIa has also been shown to enhance thrombin generation on already thrombin-activated platelets in the absence of factors VIII and IX. [15] The decision to perform a transfusion depends on the hemodynamic status and the presence of comorbid conditions such as coronary ischemia and severe anemia. Active bleeding can be managed either surgically by evacuating the hematoma and ligating the bleeding vessels, or radiologically with catheter embolization. [5,16] An interesting report by Berná-Serna et al. [6] described the complementary therapeutic role of US in the reabsorption of RSH. RSH is rarely fatal, but clinicians should be aware of this possibility especially in frail elderly patients. The high mortality rate (20%) in our series can be explained by the patients accompanying hemodynamic instability and/or comorbid conditions. In the first case with atrial fibrillation, emergent surgical exploration was done because of the hemodynamic instability of the patient, and the diagnosis of RSH was made; the bleeding vessel was ligated at laparotomy. During the follow-up in the intensive care unit, she died on postoperative day 5 due to myocardial infarction. The second case, who had a history of severe chronic obstructive pulmonary disease, died of nosocomial pneumonia on the 7th day of hospitalization. The third fatal case, for whom surgery was planned because of the subsequent infection of the hematoma, developed symptoms and signs of septic shock. Based on the findings of the present study, we conclude that RSH is a rare but potentially serious problem that can occur particularly in elderly patients on anticoagulation medications. A high index of suspicion, diagnostic vigilance and rapid radiological imaging are important for expeditious conservative management. Surgery should be reserved for cases in whom hemodynamic stability can not be established. REFERENCES 1. Cherry WB, Mueller PS. Rectus sheath hematoma: review of 126 cases at a single institution. Medicine (Baltimore) 2006;85: Zengin K, Carkman S, Kiliç I, Beken E, Eyüboğlu E. Treatment approaches to rectus sheath hematoma. Ulus Travma Acil Cerrahi Derg 2007;13: Siu WT, Tang CN, Law BK, Chau CH, Li MK. Spontaneous rectus sheath hematoma. Can J Surg 2003;46: Luhmann A, Williams EV. Rectus sheath hematoma: a series of unfortunate events. World J Surg 2006;30: Donaldson J, Knowles CH, Clark SK, Renfrew I, Lobo MD. Rectus sheath haematoma associated with low molecular weight heparin: a case series. Ann R Coll Surg Engl 2007;89: Berná-Serna JD, Sánchez-Garre J, Madrigal M, Zuazu I, Berná-Mestre JD. Ultrasound therapy in rectus sheath hematoma. Phys Ther 2005;85: Osinbowale O, Bartholomew JR. Rectus sheath hematoma. Vasc Med 2008;13: Klingler PJ, Wetscher G, Glaser K, Tschmelitsch J, Schmid T, Hinder RA. The use of ultrasound to differentiate rectus sheath hematoma from other acute abdominal disorders. Surg Endosc 1999;13: Macías-Robles MD, Peliz MG, Gonzalez-Ordonez AJ. Prophylaxis with enoxaparin can produce a giant abdominal wall haematoma when associated with low doses of aspirin among elderly patients suffering cough attacks. Blood Coagul Fibrinolysis 2005;16: Rimola J, Perendreu J, Falcó J, Fortuño JR, Massuet A, Branera J. Percutaneous arterial embolization in the management of rectus sheath hematoma. AJR Am J Roentgenol 2007;188: Berná JD, Zuazu I, Madrigal M, García-Medina V, Fernández C, Guirado F. Conservative treatment of large rectus sheath hematoma in patients undergoing anticoagulant therapy. Abdom Imaging 2000;25: Moreno Gallego A, Aguayo JL, Flores B, Soria T, Hernández Cilt - Vol. 16 Sayı - No
5 Ulus Travma Acil Cerrahi Derg Q, Ortiz S, et al. Ultrasonography and computed tomography reduce unnecessary surgery in abdominal rectus sheath haematoma. Br J Surg 1997;84: Berná JD, Garcia-Medina V, Guirao J, Garcia-Medina J. Rectus sheath hematoma: diagnostic classification by CT. Abdom Imaging 1996;21: Denard PJ, Fetter JC, Zacharski LR. Rectus sheath hematoma complicating low-molecular weight heparin therapy. Int J Lab Hematol 2007;29: He S, Blombäck M, Jacobsson Ekman G, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003;1: Zissin R, Gayer G, Kots E, Ellis M, Bartal G, Griton I. Transcatheter arterial embolisation in anticoagulant-related haematoma-a current therapeutic option: a report of four patients and review of the literature. Int J Clin Pract 2007;61: Kasım - November 2010
CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014
CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014 e 55 0495 2 Emergency Department (ED)- 1 Emergency Department Throughput Median time from
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice
Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small
DVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation
Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
Thrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
Anticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
High Risk Emergency Medicine
High Risk Emergency Medicine Minor Head Injuries in Patients on Oral Anticoagulants David Thompson, MD, MPH Assistant Professor Department of Emergency Medicine No relevant financial relationships to disclose
Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
The author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 [email protected] This presentation will discuss unlabeled and investigational use of products The author
INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.
UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight
A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs
A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
Antiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
Anticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
Planning: Patient Goals and Expected Outcomes The patient will: Remain free of unusual bleeding Maintain effective tissue perfusion Implementation
Obtain complete heath history including allergies, drug history and possible drug Assess baseline coagulation studies and CBC Assess for history of bleeding disorders, GI bleeding, cerebral bleed, recent
Anticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
STROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
Anticoagulation before and after cardioversion; which and for how long
Anticoagulation before and after cardioversion; which and for how long Sameh Samir, MD Cardiovascular medicine dept. Tanta faculty of medicine Atrial fibrillation goals of management Identify and treat
PARTICULAR ASPECTS OF ANTI-THROMBOTIC TREATMENT IN HIP ARTHROPLASTY
1 UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PARTICULAR ASPECTS OF ANTI-THROMBOTIC TREATMENT IN HIP ARTHROPLASTY ABSTRACT Ph.D student DR. TRUŞCĂ PAUL TIBERIU SCIENTIFIC COORDONATOR PROF. DR.VALENTIN
Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2
Bleeding/Clotting Risk Evaluation Tools for Atrial Fibrillation Patients Before prescribing anticoagulants, providers should weigh the risk of thrombosis against the risk of bleeding. The tools below can
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
Blood products and pharmaceutical emergencies
Blood products and pharmaceutical emergencies Kasey L. Bucher PharmD, BCPS Clinical Specialist, Emergency Medicine Mercy Health Saint Mary s September 12, 2013 Disclosures None significancemagazine.com
Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery
Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery Position Statement There is currently insufficient data for the (AOFAS) to recommend for or against routine VTED prophylaxis for
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
New Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options?
Patient decision aid Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options? http://guidance.nice.org.uk/cg180/patientdecisionaid/pdf/english Published: June 2014 About
Confirmed Deep Vein Thrombosis (DVT)
Confirmed Deep Vein Thrombosis (DVT) Information for patients What is deep vein thrombosis? Blood clotting provides us with essential protection against severe loss of blood from an injury to a vein or
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
Clinical guidance for MRI referral
MRI for cervical radiculopathy Referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of spine for a patient 16 years or older for suspected: cervical radiculopathy
New Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
Chest Pain. Acute Myocardial Infarction: Differential Diagnosis and Patient Management. Common complaint in ED. Wide range of etiologies
Acute Myocardial Infarction: Differential Diagnosis and Patient Management Presented By: Barbara Furry, RN-BC, MS, CCRN, FAHA Director The Center of Excellence in Education Director of HERO Chest Pain
Cardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?
Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning A Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning Drugs to Prevent Abnormal Blood
Guideline Statement for the Treatment of Disseminated Intravascular Coagulation
Guideline Statement for the Treatment of Disseminated Intravascular Coagulation Introduction Though a rare occurrence in the perioperative setting, disseminated intravascular coagulation (DIC) is a syndrome
Thrombophilia. Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003
Thrombophilia Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003 Thrombophilia Hereditary and acquired risk factors for thrombosis Venous thromboembolism Arterial thromboembolism
Traditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
Endovascular Repair of an Axillary Artery Aneurysm: A Novel Approach
Endovascular Repair of an Axillary Artery Aneurysm: A Novel Approach Bao- Thuy D. Hoang, MD 1, Jonathan- Hien Vu, MD 2, Jerry Matteo, MD 3 1 Department of Surgery, University of Florida College of Medicine,
Recommendations on Use of Dabigatran in Atrial Fibrillation
Recommendations on Use of Dabigatran in Atrial Fibrillation Developed by participants from the Section of Hematology/Oncology and Section of Cardiology, and Faculty of Pharmacy, University of Manitoba
New Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
Are there sufficient indications for switching to new anticoagulant agents
Are there sufficient indications for switching to new anticoagulant agents Meyer Michel Samama et Gregoris Gerotziafas Groupe Hémostase-Thrombose Hôtel-Dieu, Hôpital Tenon, Paris & Biomnis Ivry/seine,
INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
Antithrombotic therapy
Orthogeriatrics Clinical Summary Document Antithrombotic therapy Topics Preexisting anticoagulation and timing of surgery Reversal of anticoagulation Perioperative thromboprophylaxis When should we be
MANAGING BLEEDING IN THE
MANAGING BLEEDING IN THE SETTING OF NEW ANTICOAGULANTS: HOW DO OLD METHODS MEASURE UP? Michelle Zeller MD Clinical Hematology Fellow November 5th, 2011 A FRIDAY NIGHT ON-CALL WITH DR. B. LUD Very keen
1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
A Patient s Guide to Minimally Invasive Abdominal Aortic Aneurysm Repair
A Patient s Guide to Minimally Invasive Abdominal Aortic Aneurysm Repair Table of Contents The AFX Endovascular AAA System............................................ 1 What is an Abdominal Aortic Aneurysm
Investor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
Bios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
0.9% Sodium Chloride injection may be used in most cases.
Table 2. Alternatives to Heparin Sodium in Selected Situations 12-14 Situation Alternative Dose Maintain patency of peripheral venous catheters* 21-26 0.9% Sodium Chloride injection may be used in most
Service Specification Template Department of Health, updated June 2015
Service Specification Template Department of Health, updated June 2015 Service Specification No. : 2 Service: Commissioner Lead: Provider Lead: Period: Anti-coagulation monitoring Date of Review: 31 st
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
Complications of Femoral Catheterization. Daniel Kaufman, MD University Hospital of Brooklyn December 16, 2005
Complications of Femoral Catheterization Daniel Kaufman, MD University Hospital of Brooklyn December 16, 2005 Case Presentation xx yr old female presents with fever, chills, and painful swelling of R groin
STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE
STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE CASE REPORT: ACUTE STROKE MANAGEMENT 90 YEAR OLD WOMAN, PREVIOUSLY ACTIVE AND INDEPENDENT, CHRONIC ATRIAL FIBRILLATION,
GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY
BLOOD CONSERVATION STRATEGIES IN CARDIAC SURGERY: MORE IS BETTER GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY DIMITRIOS V. AVGERINOS MD, PhD, FACS, FACC Department of Cardiac Surgery,
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
Venous Thromboembolic Treatment Guidelines
Venous Thromboembolic Treatment Guidelines About the NYU Venous Thromboembolic Center (VTEC) The center s mission is to deliver advanced screening, detection, care, and management services for patients
FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE
www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.
CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99)
CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99) March 2014 2014 MVP Health Care, Inc. CHAPTER 9 CHAPTER SPECIFIC CATEGORY CODE BLOCKS I00-I02 Acute rheumatic fever I05-I09 Chronic rheumatic heart
CLINICAL PRACTICE GUIDELINE: MOBILITY WITH A DEEP VEIN THROMBOSIS (DVT) Page 1 of 10
Page 1 of 10 1.0 FOCUS: Mobilization with a Deep Vein Thrombosis (DVT). The purpose of this clinical practice guideline (CPG) is to ensure that new knowledge is integrated across Fraser Health and to standardize
ECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents Abbreviations AF: Atrial fibrillation ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic
I know my value. Be an active part of your anticoagulation therapy with INR self-monitoring
I know my value Be an active part of your anticoagulation therapy with INR self-monitoring INR* self-monitoring needs only a drop of blood, is easy, fast and decreases the possibility Be involved in your
Recommendations: Other Supportive Therapy of Severe Sepsis*
Recommendations: Other Supportive Therapy of Severe Sepsis* K. Blood Product Administration 1. Once tissue hypoperfusion has resolved and in the absence of extenuating circumstances, such as myocardial
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
The Fatal Pulmonary Artery Involvement in Behçet s Disease
The Fatal Pulmonary Artery Involvement in Behçet s Disease Dr. Vedat Hamuryudan Div. Rheumatology, Dept. Internal Medicine Cerrahpasa Medical Faculty, University of Istanbul 33 years old man Sept 2011:
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
National Patient Safety Goals Effective January 1, 2015
National Patient Safety Goals Effective January 1, 2015 Goal 1 Improve the accuracy of resident identification. NPSG.01.01.01 Long Term are ccreditation Program Medicare/Medicaid ertification-based Option
Backgrounder. Current anticoagulant therapies
Backgrounder Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Current anticoagulant therapies Anticoagulant drugs have significantly reduced the risk of thromboembolic events
3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
Tranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies
Overview Where We Use It And Why Andreas Antoniou, M.D., M.Sc. Department of Anesthesia and Perioperative Medicine University of Western Ontario November 14 th, 2009 Hemostasis Fibrinolysis Aprotinin and
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding
Lupus anticoagulant Pocket card
Lupus anticoagulant Pocket card Issue number 5 2012 Antiphospholipid Syndrome 1 The antiphospholipid syndrome (APS) is diagnosed in patients with recurrent thromboembolic events and /or pregnancy loss
LIVER CANCER AND TUMOURS
LIVER CANCER AND TUMOURS LIVER CANCER AND TUMOURS Healthy Liver Cirrhotic Liver Tumour What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood
Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
Preoperative Laboratory and Diagnostic Studies
Preoperative Laboratory and Diagnostic Studies Preoperative Labratorey and Diagnostic Studies The concept of standardized testing in all presurgical patients regardless of age or medical condition is no
East Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI
Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI Overview of Hematology, http://www.nu.edu.sa/userfiles/mhmorsy/h
4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
